Sanofi Elitek approved
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi-Synthelabo's recombinant urate-oxidase enzyme Elitek (rasburicase) is approved July 12 for "initial management of plasma uric acid levels in pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid." Phase IV commitments include development of a validated immunogenicity assay, collecting serum samples from all study patients until the assay is developed, a study in at least 150 patients assessing repetitive treatment with rasburicase, and a study comparing the approved dose and schedule of rasburicase with a regimen of sequential rasburicase and allopurinol, a competing product indicated for hyperuricemia. Sanofi plans to launch Elitek in mid-August. The firm projects worldwide sales will reach EUR 100 mil. in 2005; rasburicase was launched in Europe in 2001 under the brand Fasturtec
You may also be interested in...
QUOTED. 25 February 2021. Adam Saltman.
A recent FDA action plan on artificial intelligence and machine learning (AI/ML) medical software could encourage more to jump in, said Eko Chief Medical Officer Adam Saltman.
Daiichi's Novel EZH Candidate Moves Ahead With New Consortium Trial
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
J&J's COVID-19 Vaccine May Face Efficacy Comparison Questions At US FDA Panel Review
Efficacy against moderate to severe/critical COVID-19 was 66%-67%, well above the FDA’s stated 50% efficacy threshold for an EUA but far short of the 94%+ efficacy rates posted by the Pfizer and Moderna vaccines against symptomatic disease; agency says efficacy against specific variants cannot be evaluated at this time because sequencing data are incomplete.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: